Ukrainian DefenceTech Startup Swarmer Soars on Nasdaq: Shares Increase Several-Fold Shares of the Ukrainian DefenceTech company Swarmer experienced rapid growth on their first day of trading following the company’s debut on the Nasdaq Capital Market in the United States. This performance reflects strong investor interest in Ukraine’s defense technology sector. Swarmer, founded in 2023 by Serhiy Kuprienko and Alex Fink, develops software for the simultaneous […] Post Ukrainian DefenceTech Startup Swarmer Soars on Nasdaq: Shares Increase Several-Fold at Root-Nation.com.

Ukrainian DefenceTech Startup Swarmer Soars on Nasdaq: Shares Increase Several-Fold #UkrainianTech #DefenceTechnology #Swarmer #NasdaqDebut #IPO

Propanc Biopharma raises $4 million in Nasdaq debut, plans cancer trials Propanc Biopharma Inc. (PPCB) completed an initial public offering and began trading on the Nasdaq Capital Market on August 15. The biopharmaceutical company raised $4 million through the sale of 1 million shares at $4.00 per share, with the offering closing on August 18. The Melbourne-based company develops cancer treatments using pancreatic proenzymes. Its lead product candidate, PRP, consists of trypsinogen and chymotrypsinogen from bovine pancreas administered intravenously. The company plans to submit a clinical trial application for a Phase 1B study by the first half of 2026, targeting 30 to 40 advanced cancer patients with solid tumors at Peter Mac Cancer Center in Australia. "The Propanc management team are excited to achieve our goal of completing our initial public offering and up-listing to Nasdaq, which will help advance PRP into the clinic," said James Nathanielsz, chief executive officer. The company expanded its leadership team in mid-August, appointing a chief financial officer and two non-executive directors. Propanc also granted underwriters a 45-day option to purchase up to 150,000 additional shares at the offering price. Following the planned Phase 1B study, the company intends to initiate two 18-month Phase 2 studies evaluating PRP in up to 60 patients each with pancreatic adenocarcinoma and epithelial ovarian cancer. The company is also developing Rec-PRP, a synthetic version of its lead compound, with pharmacology studies planned for the first quarter of 2026. Propanc has raised approximately $30 million since its founding, according to the company’s statement. 3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads. That's one option, but what if there are better opportunities hiding in plain sight? Investing.com's ProPicks AI has identified growth stocks that often get overlooked by individual investors. Compare your choice against our global range of AI-selected picks - with 3 out of 4 beating their benchmark index year to date and 98% in the green. Get fresh new picks every month, now available at 50% off while our Summer Sale lasts. Hurry, offer ends soon!

Click Subscribe #PropancBiopharma #NasdaqDebut #CancerResearch #Biopharmaceuticals #InvestmentNews

Click Subscribe. #BainCapital #Heartflow #NasdaqDebut #InvestmentNews #TechStartups

Click Subscribe #EtherMachine #Cryptocurrency #NasdaqDebut #CryptoInvesting #Blockchain

Click Subscribe #Masonglory #NasdaqDebut #IPO #StockMarket #Investing

Debt collector Jefferson Capital valued at $1.2 billion in strong Nasdaq debut By Prakhar Srivastava (Reuters) -Private equity-backed Jefferson Capital has secured a valuation of $1.2 billion after its shares rose 26.7% in their Nasdaq debut on Thursday, signaling a steady recovery in investor appetite for listings with strong fundamentals. The consumer debt collector’s shares opened at $19 apiece, above its offer price of $15 per share. The Minneapolis, Minnesota-based company and some existing investors raised $150 million by selling 10 million shares in the IPO. The U.S. IPO market has recovered in recent weeks after President Donald Trump’s shifting trade policies rattled investors and froze new listings earlier this year. The rebound is likely to be selective, led by high-quality and long-anticipated issuers, IPOX research associate Lukas Muehlbauer said. Jefferson’s total revenue jumped 34.1% to $433.3 million in 2024 compared with the previous year, continuing a steady trajectory since 2019. The debut mirrors strong first-day performances last week of cancer diagnostic firm Caris Life and Slide Insurance. Stablecoin issuer Circle Internet and digital bank Chime also made stellar debuts earlier this month. But companies such as eToro, Voyager, and Omada, hot on debut, are trading below opening price as of last close. "The initial pop is often fueled by the scarcity of an allocation, while the subsequent trading helps establish a more sustainable, long-term market price. Ultimately, this dynamic is less about fading interest and more about the market undertaking a healthy process of price discovery," said Muehlbauer. The company, which competes with PRA Group and Encore Capital (NASDAQ:ECPG) Group in its core U.S. market, was acquired by U.S.-based private equity firm J.C. Flowers in 2018.

Click Subscribe #JeffersonCapital #DebtCollector #NasdaqDebut #FinancialNews #Investing

Click Subscribe #CarisLifeSciences #NasdaqDebut #StockMarketNews #Investing #Finance

Stock trading app eToro pops 40% in Nasdaq debut after pricing IPO above its expected range - CNBC Stock trading app eToro pops 40% in Nasdaq debut after pricing IPO above its expected range  CNBC

Click Subscribe #eToro #NasdaqDebut #IPO #StockTrading #Investing

eToro Set For Nasdaq Debut, Crypto And Stock Trading Platform Announces Upsized IPO Priced At $52 Per Share - Benzinga eToro Set For Nasdaq Debut, Crypto And Stock Trading Platform Announces Upsized IPO Priced At $52 Per Share  Benzinga http://dlvr.it/TKlYrw

eToro Set For Nasdaq Debut, Crypto And Stock Trading Platform Announces Upsized IPO Priced At $52 Per Share - Benzinga #eToro #NasdaqDebut #IPO #CryptoTrading #StockMarket

Chinese tea chain Chagee valued at $6.2 billion as shares pop in Nasdaq debut (Reuters) - Chinese tea chain Chagee secured a valuation of $6.2 billion after its shares gained 21% in their Nasdaq debut on Thursday, defying volatility stemming from the United States’ trade war with Beijing. The company’s American depositary shares opened at $33.75 apiece, compared with the initial public offering price of $28. Chagee sold 14.7 million ADS at the top of its marketed range of $26 to $28 per share to raise $411 million, in the biggest listing for a Chinese consumer company since vaping firm RLX Technology’s $1.4 billion IPO in January 2021, according to Dealogic data. The market reaction underscores sustained investor confidence in Beijing’s promises to boost domestic consumption and support capital markets, as confidence sours among businesses and consumers from an all-out economic war between the two largest world economies. "Many China-linked IPOs we have seen recently are plays on the growth of the Chinese consumer and therefore are relatively insulated from any tariff-linked disturbances, we believe," said IPOX CEO Josef Schuster. Chinese bubble tea firms Mixue and Guming went public in Hong Kong earlier this year. Founded in 2017 by Junjie Zhang, Chagee had nearly 6,700 teahouses worldwide at the end of March, with most of them located in premium shopping malls across China under a franchise scheme. The company generated 29.5 billion yuan ($4.03 billion) in sales last year. Four cornerstone investors, including CDH Investment Management and fund manager Redwheel, had indicated their interest on buying $205 million worth of ADSs sold in the IPO. Redwheel is one of the biggest investors in British retailer Marks & Spencer (OTC:MAKSY). Zhang will continue to own nearly 54% of the company’s Class B shares that carry 10 votes each, giving him 89% of the total voting power. ALL OPTIONS ON THE TABLE The amount raised by Chinese companies on U.S. exchanges has dropped 91%% from 2021 to $1.39 billion in 2024, according to Dealogic data, after Chinese ride-hailing giant Didi Global was forced to delist its shares following a backlash from Chinese regulators. Treasury Secretary Scott Bessent did not rule out removing Chinese stocks from U.S. exchanges in an interview with Fox Business Network last week, saying that all options were on the table. U.S. investors might have up to 40% of their equities in international companies, according to Matt Kennedy, senior strategist at Renaissance Capital, a provider of IPO-focused research and ETFs. "China will be a sizable chunk of that."

Click Subscribe #Chagee #ChineseTea #NasdaqDebut #StockMarket #Investment

🚀 ServiceTitan shares closed up 42.25% at $101 in its Nasdaq debut, with a market cap of $8.9B after raising $625M in its IPO. 📈 Big moves in the #Tech sector! #IPO #NasdaqDebut #ServiceTitan #StockMarket #TechNews #Investing #FinTech #MarketGrowth #Startups #Entrepreneurship

Coincheck Makes Bold Nasdaq Debut as Japanese Crypto Pioneer Following Coinbase’s 2021 IPO, Coincheck is the second regulated cryptocurrency company to debut on Nasdaq. The parent company…

Following Coinbase’s 2021 IPO, Coincheck is the second regulated cryptocurrency company to debut on Nasdaq. The parent company… #Crypto #Coincheck #NasdaqDebut

Trump Media & Technology Group makes a strong debut on Nasdaq, closing up 16% at $57.99 per share after the DWAC merger. The unprofitable company now valued at $7.9B. #TrumpMedia #DWAC #NasdaqDebut #StockMarket